Introduction
Methods
Study Designs
Endpoints and Statistical Analyses
Results
Baseline characteristics | Uncontrolled on OAD(s) | Uncontrolled on basal insulin | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DUAL I extension | DUAL IV | DUAL II | ||||||||||||
Global trial population | Indian subpopulation | Global trial population | Indian subpopulation | Global trial population | Indian subpopulation | |||||||||
IDegLira | IDeg | Lira | IDegLira | IDeg | Lira | IDegLira | Placebo | IDegLira | Placebo | IDegLira | IDeg | IDegLira | IDeg | |
Number of people (n) | 833 | 413 | 414 | 125 | 65 | 61 | 289 | 146 | 46 | 18 | 199 | 199 | 32 | 32 |
Age (years) | 55.1 (9.9) | 54.9 (9.7) | 55.0 (10.2) | 51.7 (10.0) | 50.9 (9.0) | 51.1 (8.1) | 60.0 (9.6) | 59.4 (10.8) | 53.2 (7.9) | 49.1 (8.8) | 57 (9) | 58 (11) | 54.2 (8.9) | 51.0 (9.5) |
Male sex, n (%) | 435 (52.2%) | 200 (48.4%) | 208 (50.2%) | 68 (54.4%) | 33 (50.8%) | 37 (60.7%) | (53.3%) | (50.0%) | 21 (45.7%) | 6 (33.3%) | (56%) | (53%) | 17 (53.1%) | 15 (46.9%) |
Body weight (kg) | 87.2 (19.0) | 87.4 (19.2) | 87.4 (18.0) | 69.1 (13.7) | 73.8 (16.7) | 72.6 (13.0) | 87.2 (18.6) | 89.3 (17.5) | 68.0 (11.4) | 68.4 (9.9) | 95.4 (19) | 93.5 (20) | 78.5 (13.8) | 81.7 (12.0) |
BMI (kg/m2) | 31.2 (5.2) | 31.2 (5.3) | 31.3 (4.8) | 26.9 (4.9) | 28.7 (5.4) | 27.9 (4.6) | 31.2 (4.8) | 32.0 (4.5) | 27.1 (3.7) | 28.6 (3.4) | 33.6 (6) | 33.8 (6) | 30.8 (4.6) | 32.3 (4.5) |
Duration of diabetes (years) | 6.6 (5.1) | 7.0 (5.3) | 7.2 (6.1) | 5.62 (4.89) | 4.93 (4.37) | 5.72 (4.74)a
| 9.0 (5.5) | 9.3 (6.5) | 6.33 (4.71) | 5.05 (3.69) | 10 (6) | 11 (7) | 10.24 (4.16) | 9.32 (5.85) |
HbA1c
| ||||||||||||||
% | 8.3 (0.9) | 8.3 (1.0) | 8.3 (0.9) | 8.3 (0.9) | 8.6 (1.0) | 8.3 (1.0) | 7.9 (0.6) | 7.9 (0.6) | 8.0 (0.5) | 8.1 (0.7) | 8.7 (0.7) | 8.8 (0.7) | 9.0 (0.7) | 9.1 (0.7) |
mmol/mol | 67 (10) | 67 (11) | 67 (10) | 67 (10) | 71 (11) | 67 (11) | 63 (7) | 63 (7) | 64 (5) | 65 (8) | 71 (8) | 73 (8) | 75 (8) | 76 (8) |
FPG (mmol/L) | 9.2 (2.4) | 9.4 (2.7) | 9.0 (2.6) | 8.6 (2.1) | 8.9 (2.5) | 8.8 (2.9)a
| 9.1 (2.2) | 9.1 (2.1) | 8.1 (2.1) | 7.8 (1.7) | 9.7 (2.9) | 9.6 (3.1) | 8.9 (2.4) | 8.9 (2.5) |
OAD at screening, n (%) | ||||||||||||||
Metformin | 691 (83.0%) | 343 (83.1%) | 338 (81.6%) | 88 (70.4%) | 42 (64.6%) | 37 (60.7%) | 95 (48%) | 98 (49%) | 4 (12.5%) | 5 (15.6%) | ||||
Metformin + pioglitazone | 142 (17.0%) | 70 (16.9%) | 75 (18.1%) | 37 (29.6%) | 23 (35.4%) | 24 (39.3%) | ||||||||
Metformin + SU | 259 (89.6%) | 129 (88.4%) | 45 (97.8%) | 16 (88.9%) | 104 (52%) | 101 (51%) | 28 (87.5%) | 27 (84.4%) | ||||||
SU | 30 (10.4%) | 17 (11.6%) | 1 (2.2%) | 2 (11.1%) |
Glucose Control
Body Weight
Insulin Dose
Safety Endpoints
Adverse events | Uncontrolled on OAD(s) | Uncontrolled on basal insulin | |||||
---|---|---|---|---|---|---|---|
DUAL I extension | DUAL IV | DUAL II | |||||
IDegLira | IDeg | Lira | IDegLira | Placebo | IDegLira | IDeg | |
Global trial population | |||||||
Number of exposed participants | 825 | 412 | 412 | 288 | 146 | 199 | 199 |
Percentage of participants with AEs | 71.2 | 70.6 | 77.2 | N/Aa
| N/Aa
| 57.8 | 61.3 |
AE rate per 100 PYE | 407.9 | 383.3 | 507.3 | 401.4 | 367.0 | 398.1 | 355.5 |
Percentage of participants with SAEs | 4.6 | 5.3 | 5.8 | N/Aa
| N/Aa
| 3.5 | 5.5 |
SAE rate per 100 PYE | 6.7 | 8.9 | 9.3 | 20.3 | 8.0 | 12.0 | 14.4 |
Indian subpopulation | |||||||
Number of exposed participants | 125 | 65 | 60 | 45 | 18 | 32 | 32 |
Percentage of participants with AEs | 76.8 | 76.9 | 93.3 | 80.0 | 61.1 | 81.3 | 87.5 |
AE rate per 100 PYE | 364.1 | 332.1 | 543.3 | 363.4 | 349.5 | 766.5 | 577.0 |
Percentage of participants with SAEs | 2.4 | 1.5 | 5.0 | 0.0 | 0.0 | 3.1 | 3.1 |
SAE rate per 100 PYE | 3.6 | 1.7 | 6.8 | 0.0 | 0.0 | 6.8 | 13.8 |